secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apyx Medical Corp (APYX)
CIK:        0000719135
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0000719135-22-000062
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apyx Medical Q2 revenue down 8% YoY; narrows 2022 guidance
----------------------------------------------------------

- Total revenue $10.3M (-8% YoY); Advanced Energy revenue $8.4M (-16% YoY), OEM $1.9M (+55%).
- Net loss $5.4M ($0.16 loss per share) vs $4.0M loss in Q2 2021; Adj. EBITDA loss $3.4M vs $2.4M.
- Full-year revenue guidance narrowed to $51-56.4M (prev $52.5-59M); net loss guidance widened to $20.1-16.6M.
- FDA granted 510(k) clearance for Renuvion Dermal Handpiece (wrinkles) and APR Handpiece (lax skin).
- International Advanced Energy generator and handpiece sales fell >45% and >30% YoY respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/719135/000071913522000062/0000719135-22-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/719135/000071913522000062/apyx-20220811.htm
  HTML page:      https://secwatch.observer/filing/0000719135-22-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer